Clinical Trials Logo

Clinical Trial Summary

A phase 1B study to explore the maximum tolerated dose (MTD) of dalpiciclib + chidamide in HR+/HER2- advanced breast cancer after the failure of CDK4/6 inhibitor therapy


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05586841
Study type Interventional
Source Beijing 302 Hospital
Contact Jinmei Zhou, Doctor
Phone +86-010-66947250
Email jinzhu2714@sina.com
Status Not yet recruiting
Phase Phase 1
Start date November 1, 2022
Completion date November 30, 2025